Request a Rep

Resources for Your Office

Download icon over RhoGAM half-life infographic

Half-life Leave Behind

Highlights the clinical significance of a longer half-life in protecting Rh-negative mothers through delivery.

Download icon over RhoGAM administration brief guide

Administration Guide

A step-by-step guide to safely administering RhoGAM and activating the safety shield.

Download icon over RhoGAM dosing guidance sheet

Dosing Sheet

A concise guide explaining the proper timing for RhoGAM administration.

Download icon over RhoGAM patient education brochure

Patient Brochure

Explains Rh sensitization, HDFN, and RhoGAM in a patient-friendly manner.

Download icon over RhoGAM patient identification card

Control Form &
Patient ID Card

Documentation tools used to track medical records and ensure compliance with safety standards when administering RhoGAM.

Download icon over RhoGAM product overview and comparison sheet

Anti-D Comparison Sheet

Compare the differences between RhoGAM to other RhIG brands.

Educational Videos

Video thumbnail of three healthcare professionals standing together with play button icon

RhoGAM Overview

Three healthcare professionals—an obstetrician, a nurse, and a blood banker—review the history and heritage of RhoGAM, along with key clinical data and important features of the RhoGAM syringe.

Pharmacist education overview graphic for RhoGAM

Hospital Pharmacist Overview

A director of pharmacy thought leader provides a hospital pharmacy perspective on RhoGAM’s heritage, clinical data, and product features.

Video thumbnail of nurse presenting RhoGAM administration training

Administration Video

Learn how to properly and safely administer an injection of RhoGAM.

The Anti-D Clinical Digest

Evidence-based insights on all things anti-D, Rh sensitization, and other related topics.

Rh Factor & Anti-D Education

Coming Soon overlay on doctor counseling patient with tablet

Rh Factor Explained

Help patients understand why Rh status matters during pregnancy and how it affects their care plan.

Coming Soon overlay on doctor counseling young woman

Counseling patients on Rh incompatibility risks

Support informed discussions with pregnant mothers about Rh status, incompatibility, and sensitization prevention.

Placeholder image for upcoming RhoGAM educational resources

Rh sensitization: what your patients need to know

Examine how sensitization occurs and the role of Rh(D) prophylaxis.

Product Information & Innovations

Coming Soon overlay on red blood cells

Safety Profile of RhoGAM: How to Address Patient Concerns

Common and rare side effects, safety considerations, and guidance on monitoring patients after RhoGAM administration.

Coming Soon overlay on red blood cells with attached antibodies

How RhoGAM works: mechanism and benefits

The mechanism of action of RhoGAM and why it is the trusted standard of care.

Coming Soon overlay on clinician typing at laptop with stethoscope

Anti-D therapy simplified: how to communicate its role to patients

How anti-D immunoglobulin works to prevent a mother’s immune response against Rh-positive fetal blood cells.

Use & Administration Protocols

Placeholder image for RhoGAM educational resources

Dosing RhoGAM: a practical guide

Step-by-step guidance on proper RhoGAM dosing and timing.

Placeholder image representing upcoming RhoGAM resources

Timing matters: when RhoGAM should be administered

The clinical timeline for RhoGAM administration, from routine antenatal care to postpartum and special situations.

Placeholder image for upcoming RhoGAM educational resources

RhoGAM & second pregnancies

When and why RhoGAM is typically administered during a second pregnancy.

Indication

  • RhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (300 μg) is an immune globulin indicated for use in preventing Rh immunization for pregnancy and other obstetrical conditions in Rh-negative women unless the father or baby is conclusively Rh-negative, e.g., delivery of an Rh-positive baby irrespective of the ABO groups of the mother and baby, any antepartum fetal-maternal hemorrhage (suspected or proven), actual or threatened pregnancy loss at any stage of gestation and ectopic pregnancy.
  • Prevention of Rh immunization in any Rh-negative person after incompatible transfusion of Rh-positive blood or blood products.
  • In the case of postpartum use, RhoGAM is intended for maternal administration. Do not inject the newborn infant.

Important Safety Information

  • RhoGAM is contraindicated in Rh-positive individuals and in patients with a known history of anaphylactic or severe systemic reactions to the administration of human immune globulin products.
  • Severe hypersensitivity reactions may occur with the use of RhoGAM. RhoGAM should be administered in a setting where appropriate equipment, medications such as epinephrine, and personnel trained in the management of hypersensitivity, anaphylaxis, and shock are available.
  • RhoGAM contains a small quantity of IgA. There is a potential risk of hypersensitivity in IgA deficient individuals. Although high doses of intravenous immune globulin containing IgA at levels of 270-720 μg/mL have been given without incident during treatment of patients with high-titer antibodies to IgA, the attending physician must weigh the benefit against the potential risks of hypersensitivity reactions.
  • Products made from human blood may carry a risk of transmitting infectious agents (e.g., viruses, the variant Creutzfeldt-Jakob disease [vCJD] and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).
  • After administration of Rho(D) immune globulin, a transitory increase of various passively transferred antibodies in the patient’s blood may yield positive serological testing results.
  • The most frequently reported adverse reactions in patients receiving Rho(D) Immune Globulin (Human) products are injection site reactions, such as swelling, induration, redness and mild pain or warmth. Possible systemic reactions are skin rash, body aches or a slight elevation in temperature. Severe systemic reactions include allergic reactions and hemolytic reactions.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

This site is intended for residents of the US only.